Firma Immunic, Autor bei PR-Web

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

Posted on 17. November 202013. December 2023 by Firma Immunic Posted in General Tagged anatomic, clinical, colitis, fiscal, immunic, immunic's, imu, lupus, market, patients, revenue, securities, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of a Scientific-Medical Advisory Board (SAB). Inaugural members include Drs. Fred D. Lublin, […]

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Posted on 6. November 202013. December 2023 by Firma Immunic Posted in General Tagged calvid, dosing, immunic, immunic's, imu, market, patients, revenue, rrms, statements, syndrome, uhcw, unblinded, vtl, with

– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 – – 200 Patients Randomized in Phase 2 Trial of […]

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Posted on 2. November 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged calvid, cell, cells, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and randomized 200 patients, pre-specified in the protocol as sufficient to […]

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

Posted on 20. October 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged calvid, fiscal, hepatitis, immunic, immunic's, imu, innovfin, market, patients, revenue, statements, syndrome, ulcerative, vaccines, with

European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19 IMU-838 is an orally available small molecule, which, because of its broad-spectrum antiviral effect […]

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

Posted on 28. September 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged calvid, dynamics, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, unblinded, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase […]

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

Posted on 11. September 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged 45mg, brain, dosing, immunic, immunic's, imu, market, neutropenia, patients, revenue, rrms, statements, syndrome, vidofludimus, with

Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations T ime Course of MRI Lesion Suppression Shows Reduction of Lesions Already Present at First Post-Baseline Scan at Week 6, Validating Rapid Attainment of Stable Therapeutic Drug […]

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Posted on 10. August 202013. December 2023 by Firma Immunic Posted in General Tagged clinical, expenses, financial, fiscal, immunic, immunic's, imu, jurisdiction, prospectus, report, revenue, securities, statements, svb, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 5,750,000 shares of its common stock at […]

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Posted on 5. August 202013. December 2023 by Firma Immunic Posted in General Tagged clinical, expenses, financial, fiscal, immunic, immunic's, imu, jurisdiction, prospectus, report, revenue, securities, statements, svb, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock […]

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

Posted on 4. August 202013. December 2023 by Firma Immunic Posted in General Tagged clinical, financial, fiscal, immunic, immunic's, jurisdiction, market, prospectus, report, revenue, sandler, securities, statements, svb, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell 5 million shares of its common stock […]

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Posted on 3. August 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged 4sc, altium, brain, fiscal, immunic, immunic's, imu, liver, market, patients, revenue, rrms, statements, syndrome, with

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis Statistically Significant Reduction of 62% and 70% in Combined Unique Active Magnetic Resonance Imaging Lesions in 45mg and 30mg Patient Cohorts, […]